Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Human hepatoma cell line HuH-7 is an effective cellular system to produce recombinant factor IX with improved post-translational modifications.

Enjolras N, Dargaud Y, Pérot E, Guillaume F, Becchi M, Négrier C.

Thromb Res. 2012 Nov;130(5):e266-73. doi: 10.1016/j.thromres.2012.08.313. Epub 2012 Sep 25.

PMID:
23021500
2.

In vivo efficacy of human recombinant factor IX produced by the human hepatoma cell line HuH-7.

Enjolras N, Perot E, Le Quellec S, Indalecio A, Girard J, Negrier C, Dargaud Y.

Haemophilia. 2015 Jul;21(4):e317-21. doi: 10.1111/hae.12688. Epub 2015 May 15.

PMID:
25981983
3.

Biochemical characterization of recombinant factor IX.

Bond M, Jankowski M, Patel H, Karnik S, Strang A, Xu B, Rouse J, Koza S, Letwin B, Steckert J, Amphlett G, Scoble H.

Semin Hematol. 1998 Apr;35(2 Suppl 2):11-7. Review.

PMID:
9565161
4.

Differential investigations from plasma-derived and recombinant Factor IX revealed major differences in post-translational modifications of activation peptides.

Chevreux G, Faid V, Andre MH, Tellier Z, Bihoreau N.

Vox Sang. 2013 Feb;104(2):171-4. doi: 10.1111/j.1423-0410.2012.01649.x. Epub 2012 Sep 10.

PMID:
22958127
5.

Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.

Perot E, Enjolras N, Le Quellec S, Indalecio A, Girard J, Negrier C, Dargaud Y.

Thromb Res. 2015 May;135(5):1017-24. doi: 10.1016/j.thromres.2015.02.034. Epub 2015 Mar 10.

PMID:
25795563
6.

The manufacturing process for recombinant factor IX.

Harrison S, Adamson S, Bonam D, Brodeur S, Charlebois T, Clancy B, Costigan R, Drapeau D, Hamilton M, Hanley K, Kelley B, Knight A, Leonard M, McCarthy M, Oakes P, Sterl K, Switzer M, Walsh R, Foster W.

Semin Hematol. 1998 Apr;35(2 Suppl 2):4-10. Review.

PMID:
9565160
7.

Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.

Brinkhous KM, Sigman JL, Read MS, Stewart PF, McCarthy KP, Timony GA, Leppanen SD, Rup BJ, Keith JC Jr, Garzone PD, Schaub RG.

Blood. 1996 Oct 1;88(7):2603-10.

PMID:
8839853
8.

Sex hormones affect the production of recombinant Factor IX in CHO and HEK-293 cell lines.

Dadehbeigi N, Ostad SN, Faramarzi MA, Ghahremani MH.

Biotechnol Lett. 2008 Nov;30(11):1909-12. doi: 10.1007/s10529-008-9774-6. Epub 2008 Jun 26.

PMID:
18581062
9.

Anion-exchange purification of recombinant factor IX from cell culture supernatant using different chromatography supports.

Ribeiro DA, Passos DF, Ferraz HC, Castilho LR.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Nov 1;938:111-8. doi: 10.1016/j.jchromb.2013.09.002. Epub 2013 Sep 7.

PMID:
24076525
10.

Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.

Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL; Recombinant Factor IX Study Group.

Blood. 2001 Dec 15;98(13):3600-6.

PMID:
11739163
11.

Expression of biologically active human clotting factor IX in Drosophila S2 cells: γ-carboxylation of a human vitamin K-dependent protein by the insect enzyme.

Vatandoost J, Zomorodipour A, Sadeghizadeh M, Aliyari R, Bos MH, Ataei F.

Biotechnol Prog. 2012 Jan-Feb;28(1):45-51. doi: 10.1002/btpr.723. Epub 2011 Oct 19.

PMID:
22012919
12.

Preclinical studies of recombinant factor IX.

Schaub R, Garzone P, Bouchard P, Rup B, Keith J, Brinkhous K, Larsen G.

Semin Hematol. 1998 Apr;35(2 Suppl 2):28-32. Review.

PMID:
9565164
13.
14.

Two novel mutations in EGF-like domains of human factor IX dramatically impair intracellular processing and secretion.

Enjolras N, Plantier JL, Rodriguez MH, Rea M, Attali O, Vinciguerra C, Negrier C.

J Thromb Haemost. 2004 Jul;2(7):1143-54.

PMID:
15219198
15.

Characterization of a monoclonal antibody B1 that recognizes phosphorylated Ser-158 in the activation peptide region of human coagulation factor IX.

Atoda H, Yokota E, Morita T.

J Biol Chem. 2006 Apr 7;281(14):9314-20. Epub 2006 Feb 8.

PMID:
16467297
16.

In vitro and in vivo functional characterization of bovine vitamin K-dependent gamma-carboxylase expressed in Chinese hamster ovary cells.

Rehemtulla A, Roth DA, Wasley LC, Kuliopulos A, Walsh CT, Furie B, Furie BC, Kaufman RJ.

Proc Natl Acad Sci U S A. 1993 May 15;90(10):4611-5.

PMID:
8506307
17.

Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study.

Poon MC, Lillicrap D, Hensman C, Card R, Scully MF.

Thromb Haemost. 2002 Mar;87(3):431-5.

PMID:
11916075
18.

Posttranslational modifications of recombinant myotube-synthesized human factor IX.

Arruda VR, Hagstrom JN, Deitch J, Heiman-Patterson T, Camire RM, Chu K, Fields PA, Herzog RW, Couto LB, Larson PJ, High KA.

Blood. 2001 Jan 1;97(1):130-8.

PMID:
11133752
19.

Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy.

Rocca A, Pizzinelli S, Oliovecchio E, Santagostino E, Rocino A, Iorio A; Italian ad hoc study group.

Blood Transfus. 2011 Jan;9(1):60-9. doi: 10.2450/2010.0011-10. Epub 2010 Apr 30.

PMID:
21084016
20.

Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.

Alamelu J, Bevan D, Sorensen B, Rangarajan S.

J Thromb Haemost. 2014 Dec;12(12):2044-8. doi: 10.1111/jth.12756. Epub 2014 Nov 11.

PMID:
25315324

Supplemental Content

Support Center